◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 2160

MicroPort CardioFlow Medtech Corporation (2160) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-11

MicroPort CardioFlow Medtech Corporation (2160) operates in the Medical Devices industry and is headquartered in Shanghai, China with about 1,415 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, 2160 reported $57M in revenue and ($19M) in net income.

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally.

Interactive charts & full statements →

2160 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$57M$51M$47M$36M
Gross Profit$37M$35M$32M$24M
Operating Income (EBIT)($20M)($22M)($50M)($48M)
Net Income($19M)($7M)($66M)($66M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2160 Free Cash Flow History

2160 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$670M$372M$364M$435M
Total Liabilities$413M$63M$34M$36M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2160 viewer.

Other Companies in Medical Devices

← 2159All “0-9” companies2161 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.